Paratek Pharmaceuticals, Inc.  
Attention: Randall Brenner  
Head, Regulatory Affairs, Quality and Technical Operations  
1000 First Avenue, Suite 200  
King of Prussia, PA 19406  

Dear Mr. Brenner:  

Please refer to your supplemental new drug applications (sNDAs) dated December 13, 2018, received December 13, 2018, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for the following:  

NDA 209816/S-002 NUZYRA (omadacycline) Tablets  
NDA 209817/S-001 NUZYRA (omadacycline) Injection  

These supplemental applications, submitted as “Changes Being Effected” supplements, provide for changes in the Storage of the Diluted Infusion Solution subsection of the Preparation and Administration of NUZYRA for Injection Intravenous Solution (Section 2.5) to reduce the in-use hold time from 24 hours to 12 hours for omadacycline diluted infusion solution when stored at room temperature.  

APPROVAL & LABELING  

We have completed our review of these applications. They are approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.  

CONTENT OF LABELING  

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling, with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.  

¹ http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm
Information on submitting SPL files using eList may be found in the guidance for industry SPL Standard for Content of Labeling Technical Qs and As.\(^2\)

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental labeling applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

You must submit final promotional materials and Prescribing Information, accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at FDA.gov.\(^3\) Information and Instructions for completing the form can be found at FDA.gov.\(^4\) For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see FDA.gov.\(^5\)

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Deepak Aggarwal, Regulatory Project Manager, at 301-796-0746.

Sincerely,

{See appended electronic signature page}

Dmitri Iarikov, MD, PhD
Deputy Director
Division of Anti-Infective Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

\(^2\) We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database [https://www.fda.gov/RegulatoryInformation/Guidances/default.htm](https://www.fda.gov/RegulatoryInformation/Guidances/default.htm).

\(^3\) [http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf](http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf)

\(^4\) [http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf](http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf)

\(^5\) [http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm](http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm)

U.S. Food and Drug Administration
Silver Spring, MD 20993
www.fda.gov
ENCLOSURE(S):
  • Content of Labeling
This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

DMITRI IARIKOV
06/13/2019 10:23:29 AM